CELH
Celsius Holdings, Inc.
CELH has the edge over SLSN overall, supported by lower modeled downside and stronger fundamentals.
SLSN
Solesence, Inc. Common Stock
SLSN offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
CELH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Strong |
CELH's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
SLSN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Strong |
SLSN's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
CELH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 21x | $31.89 | — |
| Current | 35x | $31.89 | — |
| Cheap | 40x | $35.95 | +13% |
| Fair | 141x | $127 | +299% |
| Expensive | 650x | $585 | +1735% |
Historical ranges are pointers, not guarantees.
CELH's PE is in its cheap range at 35x. If earnings grow as analysts expect, today's price would be 21x next year's earnings.
SLSN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 15x | $0.91 | — |
| Cheap | 45x | $2.73 | +200% |
| Fair | 66x | $3.97 | +337% |
| Expensive | 130x | $7.78 | +755% |
Historical ranges are pointers, not guarantees.
SLSN has the edge over CELH in the historical PE scenario, which offers more potential upside but is not a forecast.
CELH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for CELH, with profitability improving. However, they disagree widely on these estimates.
SLSN Forward outlook
There aren't enough analyst estimates for SLSN to show an outlook.
CELH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.53 | +70% |
| Q3 2026 | $0.90 | +718% |
| Q2 2026 | $0.24 | -37% |
| Q1 2026 | $0.43 | +30% |
| Q4 2025 | $0.25 | -44% |
| Q3 2025 | $0.11 | -85% |
| Q2 2025 | $0.38 | -62% |
| Q1 2025 | $0.33 | -64% |
| Q4 2024 | $0.45 | -42% |
CELH earned $0.90 per share over the past year, about eight times what it earned the year before.
SLSN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.06 | +$0.08 |
| Q2 2026 | $0.00 | -100% |
| Q1 2026 | $0.04 | +$0.04 |
| Q4 2025 | $0.05 | +150% |
| Q3 2025 | -$0.02 | -200% |
| Q2 2025 | $0.03 | +$0.08 |
| Q1 2025 | $0.00 | +$0.05 |
| Q4 2024 | $0.02 | +$0.11 |
SLSN has the edge over CELH on earnings, with more consistent year-over-year improvement.
CELH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $847.2M | +17% |
| Q2 2026 | $817.9M | +11% |
| Q1 2026 | $782.6M | +138% |
| Q4 2025 | $721.6M | +117% |
| Q3 2025 | $725.1M | +173% |
| Q2 2025 | $739.3M | +84% |
| Q1 2025 | $329.3M | -7.4% |
| Q4 2024 | $332.2M | -4.4% |
CELH has the edge over SLSN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +31 points |
| Q2 2026 | 9.2% | -10 points |
| Q1 2026 | 18% | +2 points |
| Q4 2025 | 3.6% | +9.2 points |
| Q3 2025 | -11% | -9.8 points |
| Q2 2025 | 19% | -4.1 points |
| Q1 2025 | 16% | -7.6 points |
| Q4 2024 | -5.6% | -23 points |
CELH has the edge over SLSN on profitability, with a higher operating margin.
SLSN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.2M | +38% |
| Q2 2026 | $15.3M | -25% |
| Q1 2026 | $13M | -11% |
| Q4 2025 | $12.5M | -0.7% |
| Q3 2025 | $14.6M | -13% |
| Q2 2025 | $20.4M | +56% |
| Q1 2025 | $14.6M | +48% |
| Q4 2024 | $12.6M | +57% |
SLSN's revenue has held roughly level: $20M last quarter, up 38% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +25 points |
| Q2 2026 | 0.1% | -9.2 points |
| Q1 2026 | -5.2% | -7 points |
| Q4 2025 | 9.7% | +36 points |
| Q3 2025 | -4.6% | -24 points |
| Q2 2025 | 9.4% | +1.4 points |
| Q1 2025 | 1.8% | -9.5 points |
| Q4 2024 | -27% | -3.1 points |
SLSN's operating margin was 20% last quarter, up 25 points from the same quarter a year ago, near the top of its range since 2019.
CELH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $127.7M | -60% |
| Q2 2026 | $205.5M | +479% |
| Q1 2026 | $65.8M | -32% |
| Q4 2025 | -$130M | -285% |
| Q3 2025 | $321.5M | +3599% |
| Q2 2025 | $35.5M | +17% |
| Q1 2025 | $96.4M | -26% |
| Q4 2024 | $70.3M | +16394% |
CELH still generates free cash flow, though less than at its 2025 peak: $269M over the past year.
SLSN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.7M | +$9.2M |
| Q2 2026 | $191K | +$845K |
| Q1 2026 | $1.5M | +$8.7M |
| Q4 2025 | $1.8M | +$2.2M |
| Q3 2025 | -$2.5M | -190% |
| Q2 2025 | -$654K | +$388K |
| Q1 2025 | -$7.2M | -$3.3M |
| Q4 2024 | -$404K | +$2.4M |
SLSN has the edge over CELH on cash flow, with more consistent year-over-year improvement.
CELH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.8% | -2M shares |
| 1 year | -1.1% | -2.9M shares |
| 3 years | +7.4% | +17.6M shares |
| 5 years | +8.3% | +19.5M shares |
| Available history | +32% | +62.4M shares |
CELH has the edge over SLSN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $300,000 |
| Q2 2026 | $1M |
| Q1 2026 | $8.8M |
| Q4 2025 | $2.5M |
| Q3 2025 | $448,000 |
| Q2 2025 | $879,000 |
| Q1 2025 | $1.9M |
| Q4 2024 | $603,000 |
CELH spent $13M buying back its own shares over the past year, about three times what it spent the year before.
SLSN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +847K shares |
| 1 year | +1.4% | +983K shares |
| 3 years | +44% | +21.9M shares |
| 5 years | +41% | +20.8M shares |
| Available history | +95% | +34.9M shares |
SLSN has 71M diluted shares, up 1.4% from a year ago.
CELH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.1x | Net Cash |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 1.6x | Healthy |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | -7.3x | Net Cash |
| Q4 2024 | -5.5x | Net Cash |
CELH has the edge over SLSN on leverage, with a lower net debt burden relative to earnings.
SLSN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.9x | Very low |
| Q2 2026 | 2.9x | Moderate |
| Q1 2026 | 4.4x | High |
| Q4 2025 | 3.6x | Elevated |
| Q2 2025 | 3.9x | Elevated |
| Q1 2025 | 2.2x | Moderate |
| Q2 2022 | -0.4x | Net Cash |
| Q1 2022 | -0.3x | Net Cash |
SLSN's net debt is less than a year of its operating earnings (EBITDA), down from 3.9 years a year ago.
CELH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.3 | Neutral |
| Stochastic | 56.8 | Neutral |
CELH's weekly RSI is 51 (neutral) and its Stochastic is 57 (neutral).
SLSN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.9 | Neutral |
| Stochastic | 26.1 | Neutral |
SLSN's weekly RSI is 46 (neutral) and its Stochastic is 26 (neutral).
CELH PE vs Consumer Defensive Sector
| Metric | CELH | Sector median | Relative |
|---|---|---|---|
| PE | 35x | 19x | 82% above |
| PE % | 11 | 18 | 7 pts below |
CELH is trading at 35x earnings, a 82% premium to the Consumer Defensive sector's median of 19x.
SLSN PE vs Consumer Defensive Sector
| Metric | SLSN | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 19x | 22% below |
| PE % | 0 | 18 | 18 pts below |
SLSN has the edge over CELH on valuation relative to its sector.
CELH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.1 | 9.4% above |
| 20 week MA | $29.6 | 7.8% above |
| 50 week MA | $36.1 | 12% below |
| 100 week MA | $38.8 | 18% below |
| 200 week MA | $44.6 | 29% below |
CELH has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 29% below its 200-week average.
SLSN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.87 | 4.6% above |
| 20 week MA | $0.87 | 4.6% above |
| 50 week MA | $1.16 | 22% below |
| 100 week MA | $2.15 | 58% below |
| 200 week MA | $1.69 | 46% below |
SLSN has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 46% below its 200-week average.
CELH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.58 | $14.7 | +832% |
| 2021 | $14.7 | $24.9 | +69% |
| 2022 | $24.9 | $35.6 | +43% |
| 2023 | $35.6 | $54.5 | +53% |
| 2024 | $54.5 | $26.5 | -51% |
| 2025 | $26.5 | $45.6 | +72% |
| 2026 YTD | $45.6 | $31.9 | -30% |
CELH has the edge over SLSN on returns for 2026, with the stronger performance.
SLSN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $0.27 | $0.80 | +196% |
| 2021 | $0.80 | $4.24 | +430% |
| 2022 | $4.24 | $1.18 | -72% |
| 2023 | $1.18 | $0.60 | -49% |
| 2024 | $0.60 | $2.30 | +283% |
| 2025 | $2.30 | $1.81 | -21% |
| 2026 YTD | $1.81 | $0.91 | -50% |
SLSN's yearly returns have swung widely, from +430% in 2021 to −72% in 2022. It's down 50% so far in 2026.